Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro

Fig. 3

Endometrial cancer cell lines in which antagonism was observed to the combination of pictilisib (PI3Ki), apitolisib (PI3K/mTORi) and cobimetinib (MEKi). a Two cell lines in which antagonism was observed to the combination of PI3K and MEK inhibition. b Two cell lines in which antagonism was observed to the combination of PI3K/mTOR and MEK inhibition

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us